Mineralys Therapeutics (NASDAQ:MLYS) Director Daphne Karydas Sells 3,000 Shares of Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the sale, the director owned 6,200 shares in the company, valued at $155,000. This trade represents a 32.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daphne Karydas also recently made the following trade(s):

• On Tuesday, March 31st, Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $75,000.00.

Mineralys Therapeutics Stock Up 4.8%

NASDAQ MLYS opened at $25.13 on Thursday. Mineralys Therapeutics, Inc. has a 12-month low of $12.59 and a 12-month high of $47.65. The company has a market capitalization of $2.07 billion, a PE ratio of -12.26 and a beta of 0.57. The firm’s 50 day moving average is $27.64 and its 200-day moving average is $30.13.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.04. As a group, sell-side analysts expect that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current year.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MLYS. Navalign LLC acquired a new position in shares of Mineralys Therapeutics in the fourth quarter valued at $33,000. KBC Group NV acquired a new position in shares of Mineralys Therapeutics in the first quarter valued at $33,000. Smartleaf Asset Management LLC increased its holdings in shares of Mineralys Therapeutics by 198.2% in the third quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after purchasing an additional 676 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after purchasing an additional 1,107 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Mineralys Therapeutics by 1,845.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock valued at $76,000 after purchasing an additional 1,993 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MLYS. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Wall Street Zen cut Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Bank of America lifted their price target on Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Jefferies Financial Group reiterated a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Tuesday, April 21st. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Mineralys Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.